In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP explore the latest key clinical updates on BTK inhibitors in CLL, featuring insights from the randomized phase III FLAIR, SEQUOIA, and BRUIN CLL-321 trials presented at ASCO and EHA 2025. This episode unpacks evolving treatment strategies, MRD-guided approaches, and what these developments mean for oncology professionals.
In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:
Presenters:
James Davis, PharmD, BCOP
Clinical Pharmacy Specialist, Malignant Hematology
MUSC Hollings Cancer Center
Assistant Professor
MUSC College of Pharmacy
Charleston, South Carolina
Victoria Nachar, PharmD, BCOP
Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan
Link to full program:
https://bit.ly/3H2EcSX